Ergomed PLC (LON:ERGO)‘s stock had its “buy” rating reaffirmed by Numis Securities Ltd in a research report issued on Monday. They currently have a GBX 267 ($3.30) target price on the stock. Numis Securities Ltd’s price target would indicate a potential upside of 120.66% from the company’s current price.

Several other equities research analysts have also issued reports on ERGO. Stifel Nicolaus reaffirmed a “buy” rating and set a GBX 271 ($3.35) price target on shares of Ergomed PLC in a report on Friday, September 2nd. N+1 Singer reaffirmed a “buy” rating on shares of Ergomed PLC in a report on Monday, September 26th.

Shares of Ergomed PLC (LON:ERGO) opened at 120.75 on Monday. Ergomed PLC has a 12-month low of GBX 117.00 and a 12-month high of GBX 172.00. The firm has a 50-day moving average of GBX 120.15 and a 200 day moving average of GBX 131.80. The firm’s market capitalization is GBX 37.57 million.

About Ergomed PLC

Ergomed PLC is a United Kingdom-based provider of drug development services to the pharmaceutical industry. The Company’s therapeutic focus is on onology, neurology and immunology and the development of orphan drugs. Ergomed Plc manages clinical development from Phase I through to late phase programs.

Receive News & Stock Ratings for Ergomed PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed PLC and related stocks with our FREE daily email newsletter.